Wealthfront Advisers LLC Has $4.82 Million Stake in Royalty Pharma plc (NASDAQ:RPRX)

Wealthfront Advisers LLC boosted its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 1,655.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 188,935 shares of the biopharmaceutical company's stock after buying an additional 178,173 shares during the period. Wealthfront Advisers LLC's holdings in Royalty Pharma were worth $4,820,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Swedbank AB lifted its holdings in shares of Royalty Pharma by 2.0% in the third quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company's stock worth $311,964,000 after acquiring an additional 213,900 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Royalty Pharma by 1.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,009,541 shares of the biopharmaceutical company's stock worth $28,560,000 after acquiring an additional 15,963 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Royalty Pharma by 26.8% in the third quarter. Victory Capital Management Inc. now owns 849,035 shares of the biopharmaceutical company's stock worth $24,019,000 after acquiring an additional 179,411 shares during the last quarter. Main Street Financial Solutions LLC lifted its holdings in shares of Royalty Pharma by 76.1% in the third quarter. Main Street Financial Solutions LLC now owns 80,081 shares of the biopharmaceutical company's stock worth $2,265,000 after acquiring an additional 34,611 shares during the last quarter. Finally, KBC Group NV lifted its holdings in shares of Royalty Pharma by 63.1% in the third quarter. KBC Group NV now owns 41,554 shares of the biopharmaceutical company's stock worth $1,176,000 after acquiring an additional 16,081 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Up 1.2 %

Shares of NASDAQ RPRX opened at $32.85 on Thursday. The company has a 50 day simple moving average of $31.31 and a 200 day simple moving average of $28.50. The firm has a market cap of $18.94 billion, a PE ratio of 22.66, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Remove Ads

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a dividend of $0.22 per share. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.68%. Royalty Pharma's dividend payout ratio (DPR) is presently 60.69%.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.